Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

Last-mile health services company DocGo stock surges on 2023 revenue guidance

DocGo Inc posted full-year 2022 and fourth quarter results after the bell Monday, but its 2023 guidance is what caught investors’ attention.

DocGo projects 2023 revenue between $500 million to $510 million, which would represent growth of 14% to 16% over 2022 on an as-reported basis. That figure is well beyond analyst consensus projections of $493.2 million.

The company pointed to “strong demand from its customers for both mobile health and transportation services solutions.”

Shares of DocGo added 4.6% in after-hours trading.

The last-mile mobile health services company posted revenue of $108.8 million for the period ended December 31, down from $121.3 million a year earlier but ahead of the Street's expectation of $103.82 million.

Adjusted EBITDA was $6.8 million, compared to $17.3 million in the 2022 period.

The reason for the fall was a decline in Covid testing revenue. In the fourth quarter of 2021, Covid testing brought in about $50 million in revenue, but in 4Q of 2022 it only generated about $1 million.

Full-year 2022 revenue increased to $440.5 million from $318.7 million in 2021, a 38% jump.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK